ArticleBulletin of the World Health Organization2026
Seasonal malaria chemoprevention effectiveness and drug resistance in Plasmodium falciparum: a matched parallel cohort study, Kenya.
Article in Bulletin of the World Health Organization, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in a semi-nomadic community in north-western Kenya, and to examine the relationship between parasite resistance and breakthrough infections. Methods: A parallel cohort study conducted during the peak malaria season in 2024 involved 10 randomly selected villages in Turkana Central subcounty, where children younger than 5 years received seasonal malaria chemoprevention, and 10 matched villages in Turkana North subcounty (non-intervention cohort). We conducted surveillance of malaria symptoms weekly. The primary outcome was malaria-like symptoms plus a positive rapid diagnostic test result. We analysed Findings: Children (198 in the intervention cohort and 200 in the non-intervention cohort) were followed until four weeks after the last chemoprevention cycle. In the intervention cohort, 72% (143/198) completed all five cycles. The incidence of malaria was significantly lower in the intervention than non-intervention cohort (adjusted incidence rate ratio 0.29; 95% confidence interval: 0.13-0.67). Conclusion: Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine was associated with substantial protection against malaria in children in an area where sulfadoxine-pyrimethamine resistance was common. Treated children were more likely to harbour resistant parasites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.